NVO EBITDA Growth
Novo Nordisk A/S Common Stock · EBITDA Growth
NVO EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported4.66%period ending
NVO TTM EBITDA YoY % (26.87% → 4.66%)
Year-over-year change
High-resolution chart · PNG
NVO ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| 4.6643% | |
| 12.6288% | |
| 4.3729% | |
| 21.8416% | |
| 29.0736% | |
| 32.1119% | |
| 34.8668% | |
| 43.4589% | |
| 52.8798% | |
| 51.2584% | |
| 52.0627% | |
| 20.2438% | |
| 18.5516% | |
| 20.8189% | |
| 16.1227% | |
| 26.8319% | |
| 21.0829% | |
| 13.933% | |
| 10.4078% | |
| 10.8467% | |
| 6.9699% | |
| 6.1048% | |
| 8.8897% | |
| 2.6566% | |
| 7.2254% | |
| 7.3981% | |
| 5.2821% | |
| 9.8028% | |
| 4.679% | |
| 2.2396% | |
| 0.2773% | |
| -5.3199% | |
| -5.7472% | |
| -1.8755% | |
| 1.1655% | |
| 17.6047% | |
| 19.9039% | |
| 16.8846% | |
| 9.0508% | |
| -6.7864% | |
| -2.8158% | |
| 4.5342% | |
| 24.9258% | |
| 31.3937% | |
| 28.0799% | |
| 19.4204% | |
| 6.1335% | |
| 10.1218% | |
| 10.9954% | |
| 17.0285% | |
| 23.2957% | |
| 19.7353% | |
| 24.8179% | |
| 29.0207% | |
| 24.9301% | |
| 22.513% | |
| 13.501% | |
| 2.5626% | |
| 0.3244% | |
| 15.6593% | |
| 23.4008% | |
| 31.7839% | |
| 33.783% | |
| 15.659% | |
| 14.2786% | |
| 22.6697% | |
| 30.4019% | |
| 59.0897% | |
| 64.3238% | |
| 45.4097% | |
| 45.8727% | |
| 9.0027% | |
| 1.8454% | |
| 3.353% | |
| -6.5069% | |
| 5.4779% | |
| 5.7303% | |
| 7.1455% | |
| 18.6571% | |
| 17.5089% | |
| 23.871% | |
| 27.8377% | |
| 15.8147% | |
| 267.3222% | |
| 964.7672% | |
| 155.2343% | |
| 10.0104% | |
| -226.9869% | |
| -118.9009% | |
| -37.0684% | |
| 20.8837% | |
| -38.5618% | |
| -28.2035% | |
| -36.1317% | |
| -14.3859% | |
| 83.5602% | |
| -47.3497% | |
| -46.7386% | |
| -52.8164% | |
| -78.6357% |